At Antigenesis, we are pioneering next-generation biologics to address critical unmet needs in veterinary medicine. Our current pipeline focuses on canine oncology and autoimmune diseases, leveraging cutting-edge antibody therapeutics to deliver targeted, safe, and effective treatments.

With a strong foundation in AI/ML-driven discovery and translational research, our programs are designed to accelerate the path from concept to clinic. We are actively advancing multiple candidates through preclinical and clinical development, with our first wave of therapies set for commercial launch in the coming years.

This is just the beginning. Our long-term vision is to expand our biologics platform across a broader range of companion animal diseases, transforming the standard of care in veterinary medicine.